Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026

RAPID MICRO BIOSYSTEMS, INC.

2023-FY EPS reported -$1.22 revenue$22,519,000

Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).
Placed 16 Growth Direct systems in FY23, 6 in Q4; 18 validations completed in FY23.
Cash and investments ~$95M as of Dec 31, 2023; cash runway at least into H2 2026.
Growth Direct selected by Samsung Biologics; systems now placed with 100% of commercial CAR-T manufacturers.
Commercial launch of Growth Direct Rapid Sterility app expected by mid-2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 10, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.